Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Han Ah | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Park, Seung Woon | - |
dc.contributor.author | Park, Sang Jung | - |
dc.contributor.author | Kim, Tae Hyung | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | An, Hyunggin | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Um, Soon Ho | - |
dc.date.accessioned | 2021-09-03T20:33:30Z | - |
dc.date.available | 2021-09-03T20:33:30Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87670 | - |
dc.description.abstract | Background/Aims: Clear indicators for stopping antiviral therapy in chronic hepatitis B (CHB) patients are not yet available. Since the level of hepatitis B surface antigen (HBsAg) is correlated with covalently closed circular DNA, the HBsAg titer might be a good indicator of the off-treatment response. This study aimed to determine the relationship between the HBsAg titer and the entecavir (ETV) off-treatment response. Methods: This study analyzed 44 consecutive CHB patients (age, 44.6 +/- 11.4 years, mean +/- SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; HBV DNA level, 6.8 +/- 1.3 log(10) IU/mL) treated with ETV for a sufficient duration and in whom treatment was discontinued after HBsAg levels were measured. A virological relapse was defined as an increase in serum HBV DNA level of >2000 IU/mL, and a clinical relapse was defined as a virological relapse with a biochemical flare, defined as an increase in the serum alanine aminotransferase level of >2 x upper limit of normal. Results: After stopping ETV, virological relapse and clinical relapse were observed in 32 and 24 patients, respectively, during 20.8 +/- 19.9 months of follow-up. The cumulative incidence rates of virological relapse were 36.2% and 66.2%, respectively, at 6 and 12 months, and those of clinical relapse were 14.3% and 42.3%. The off-treatment HBsAg level was an independent factor associated with clinical relapse (hazard ratio, 2.251; 95% confidence interval, 1.076-4.706; P=0.031). When patients were grouped according to off-treatment HBsAg levels, clinical relapse did not occur in patients with an off-treatment HBsAg level of <= 2 log(10) IU/mL (n=5), while the incidence rates of clinical relapse at 12 months after off-treatment were 28.4% and 55.7% in patients with off-treatment HBsAg levels of >2 and <= 3 log(10) IU/mL (n=11) and >3 log(10) IU/mL (n=28), respectively. Conclusions: The off-treatment HBsAg level is closely related to clinical relapse after treatment cessation. A serum HBsAg level of <2 log(10) IU/mL is an excellent predictor of a sustained off-treatment response in CHB patients who have received ETV for a sufficient duration. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC STUDY LIVER | - |
dc.subject | HBEAG SEROCONVERSION | - |
dc.subject | ANTIVIRAL THERAPY | - |
dc.subject | VIROLOGICAL RESPONSE | - |
dc.subject | TREATMENT CESSATION | - |
dc.subject | LAMIVUDINE THERAPY | - |
dc.subject | ADEFOVIR DIPIVOXIL | - |
dc.subject | NATURAL-HISTORY | - |
dc.subject | VIRUS INFECTION | - |
dc.subject | OPEN-LABEL | - |
dc.subject | DURABILITY | - |
dc.title | Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.identifier.doi | 10.3350/cmh.2016.0047 | - |
dc.identifier.scopusid | 2-s2.0-85014868101 | - |
dc.identifier.wosid | 000407832900010 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, v.22, no.3, pp.382 - 389 | - |
dc.relation.isPartOf | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.citation.title | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.citation.volume | 22 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 382 | - |
dc.citation.endPage | 389 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002145396 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | HBEAG SEROCONVERSION | - |
dc.subject.keywordPlus | ANTIVIRAL THERAPY | - |
dc.subject.keywordPlus | VIROLOGICAL RESPONSE | - |
dc.subject.keywordPlus | TREATMENT CESSATION | - |
dc.subject.keywordPlus | LAMIVUDINE THERAPY | - |
dc.subject.keywordPlus | ADEFOVIR DIPIVOXIL | - |
dc.subject.keywordPlus | NATURAL-HISTORY | - |
dc.subject.keywordPlus | VIRUS INFECTION | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | DURABILITY | - |
dc.subject.keywordAuthor | Hepatitis B virus | - |
dc.subject.keywordAuthor | Hepatitis B surface antigen | - |
dc.subject.keywordAuthor | Relapse | - |
dc.subject.keywordAuthor | Off-treatment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.